Literature DB >> 8878440

Dermal injection of immunocytes induces psoriasis.

T Wrone-Smith1, B J Nickoloff.   

Abstract

Establishing direct and causal relationships among the confederacy of activated cell types present in psoriasis has been hampered by lack of an animal model. Within psoriatic plaques there are hyperplastic keratinocytes, infiltrating immunocytes, and activated endothelial cells. The purpose of this study was to determine if psoriasis is primarily a disorder of keratinocytes or the immune system. Using a newly developed experimental system in which full-thickness human skin is orthotopically transferred onto severe combined immunodeficient mice, autologous immunocytes were injected into dermis, and the resultant phenotype characterized by clinical, histologic, and immunophenotypic analyses. Engraftment of samples included both uninvolved/ symptomless (PN) skin removed from patients with psoriasis elsewhere, or from healthy individuals with no skin disease (NN skin). In 10 different experiments involving 6 different psoriasis patients, every PN skin was converted to a full-fledged psoriatic plaque skin by injection of autologous blood-derived immunocytes. In all but one psoriatic patient, the immunocytes required preactivation with IL-2 and superantigens to convert PN skin into psoriatic plaque skin. In every case, resultant plaques were characterized by visible presence of flaking and thickened skin, loss of the granular cell layer, prominent elongation of rete pegs with a dermal angiogenic tissue reaction, and infiltration within the epidermis by T cells. Lesional skin displayed 20 different antigenic determinants of the psoriatic phenotype. None of the four NN skin samples injected with autologous immunocytes converted to psoriatic plaques. We conclude that psoriasis is caused primarily by the ability of pathogenetic blood-derived immunocytes to induce secondary activation and disordered growth of endogenous cutaneous cells including keratinocytes and vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878440      PMCID: PMC507628          DOI: 10.1172/JCI118989

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Stress, symmetry, and psoriasis: possible role of neuropeptides.

Authors:  E M Farber; B J Nickoloff; B Recht; J E Fraki
Journal:  J Am Acad Dermatol       Date:  1986-02       Impact factor: 11.527

2.  HLA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions.

Authors:  T Terui; S Aiba; T Kato; T Tanaka; H Tagami
Journal:  Br J Dermatol       Date:  1987-01       Impact factor: 9.302

3.  The natural history of psoriasis in 5,600 patients.

Authors:  E M Farber; M L Nall
Journal:  Dermatologica       Date:  1974

4.  Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q.

Authors:  J Tomfohrde; A Silverman; R Barnes; M A Fernandez-Vina; M Young; D Lory; L Morris; K D Wuepper; P Stastny; A Menter
Journal:  Science       Date:  1994-05-20       Impact factor: 47.728

5.  Normal and psoriatic human skin grafts on "nude" mice: morphological and immunochemical studies.

Authors:  M Haftek; J P Ortonne; M J Staquet; J Viac; J Thivolet
Journal:  J Invest Dermatol       Date:  1981-01       Impact factor: 8.551

6.  Uninvolved skin from psoriatic patients develops signs of involved psoriatic skin after being grafted onto nude mice.

Authors:  J E Fraki; R A Briggaman; G S Lazarus
Journal:  Science       Date:  1982-02-05       Impact factor: 47.728

7.  Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris.

Authors:  T Henseler; E Christophers
Journal:  J Am Acad Dermatol       Date:  1985-09       Impact factor: 11.527

8.  The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis.

Authors:  B S Baker; C E Griffiths; S Lambert; A V Powles; J N Leonard; H Valdimarsson; L Fry
Journal:  Br J Dermatol       Date:  1987-04       Impact factor: 9.302

9.  Involved and uninvolved skin from psoriatic subjects: are they equally diseased? Assessment by skin transplanted to congenitally athymic (nude) mice.

Authors:  G G Krueger; D A Chambers; J Shelby
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

10.  Percutaneous penetration in the hairless dog, weanling pig and grafted athymic nude mouse: evaluation of models for predicting skin penetration in man.

Authors:  W G Reifenrath; E M Chellquist; E A Shipwash; W W Jederberg; G G Krueger
Journal:  Br J Dermatol       Date:  1984-07       Impact factor: 9.302

View more
  77 in total

1.  Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis.

Authors:  J B Travers; Q A Hamid; D A Norris; C Kuhn; R C Giorno; P M Schlievert; E R Farmer; D Y Leung
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Disease mechanisms in psoriasis and psoriatic arthritis.

Authors:  P Costello; O FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 3.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

Authors:  Brian J Nickoloff; Frank O Nestle
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

4.  A global gene expression analysis of the peripheral blood mononuclear cells reveals the gene expression signature in psoriasis.

Authors:  Sang-Keun Lee; Eun-Kyoung Jeon; Yu-Jin Kim; Sam-Hwa Seo; Chang-Deok Kim; Jong-Soon Lim; Jeung-Hoon Lee
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

Review 5.  Animal models of psoriasis and psoriatic arthritis: an update.

Authors:  Curdin Conrad; Frank O Nestle
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 6.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

7.  Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.

Authors:  Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

8.  Development of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways.

Authors:  Sara Guerrero-Aspizua; Marta García; Rodolfo Murillas; Luisa Retamosa; Nuria Illera; Blanca Duarte; Almudena Holguín; Susana Puig; Maria Isabel Hernández; Alvaro Meana; Jose Luis Jorcano; Fernando Larcher; Marta Carretero; Marcela Del Río
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

9.  Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin.

Authors:  A Tsicopoulos; J Pestel; O Fahy; H Vorng; F Vandenbusche; H Porte; L Eraldi; A Wurtz; H Akoum; Q Hamid; B Wallaert; A B Tonnel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.